Literature DB >> 23644529

AMPK: a contextual oncogene or tumor suppressor?

Jiyong Liang1, Gordon B Mills.   

Abstract

The AMP-activated protein kinase (AMPK) functions to monitor and maintain energy homeostasis at the cellular and organism level. AMPK was perceived historically primarily as a component of the LKB1/STK11 tumor suppressor (LKB1 mutations cause the Peutz-Jegher cancer predisposition syndrome) cascade upstream of the TSC1/2/mTOR pathway and thus likely to be a tumor suppressor. However, AMPK has recently been shown to promote cancer cell survival in the face of extrinsic and intrinsic stressors including bioenergetic, growth factor, and oncogene stress compatible with studies showing that AMPK is required for oncogenic transformation. Thus, whether AMPK acts as a bona fide tumor suppressor or a contextual oncogene and, of particular importance, whether AMPK should be targeted for activation or inhibition during cancer therapy, is controversial and requires clarification. We aim to initiate discussions of these critical questions by reviewing the role of AMPK with an emphasis on cancer cell adaptation to microenvironment stress and therapeutic intervention. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23644529      PMCID: PMC3725287          DOI: 10.1158/0008-5472.CAN-12-3876

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  75 in total

1.  Amplification at 11q23 targets protein kinase SIK2 in diffuse large B-cell lymphoma.

Authors:  Stefan Nagel; Ellen Leich; Hilmar Quentmeier; Corinna Meyer; Maren Kaufmann; Margarete Zaborski; Andreas Rosenwald; Hans G Drexler; Roderick A F Macleod
Journal:  Leuk Lymphoma       Date:  2010-05

Review 2.  Signaling by target of rapamycin proteins in cell growth control.

Authors:  Ken Inoki; Hongjiao Ouyang; Yong Li; Kun-Liang Guan
Journal:  Microbiol Mol Biol Rev       Date:  2005-03       Impact factor: 11.056

Review 3.  Deconvoluting the context-dependent role for autophagy in cancer.

Authors:  Eileen White
Journal:  Nat Rev Cancer       Date:  2012-04-26       Impact factor: 60.716

4.  AMPKα modulation in cancer progression: multilayer integrative analysis of the whole transcriptome in Asian gastric cancer.

Authors:  Yon Hui Kim; Han Liang; Xiuping Liu; Ju-Seog Lee; Jae Yong Cho; Jae-Ho Cheong; Hoguen Kim; Min Li; Thomas J Downey; Matthew D Dyer; Yongming Sun; Jingtao Sun; Ellen M Beasley; Hyun Cheol Chung; Sung Hoon Noh; John N Weinstein; Chang-Gong Liu; Garth Powis
Journal:  Cancer Res       Date:  2012-03-20       Impact factor: 12.701

5.  AMP-activated protein kinase induces a p53-dependent metabolic checkpoint.

Authors:  Russell G Jones; David R Plas; Sara Kubek; Monica Buzzai; James Mu; Yang Xu; Morris J Birnbaum; Craig B Thompson
Journal:  Mol Cell       Date:  2005-04-29       Impact factor: 17.970

6.  The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers.

Authors:  Kwai Wa Cheng; John P Lahad; Wen-Lin Kuo; Anna Lapuk; Kyosuke Yamada; Nelly Auersperg; Jinsong Liu; Karen Smith-McCune; Karen H Lu; David Fishman; Joe W Gray; Gordon B Mills
Journal:  Nat Med       Date:  2004-10-24       Impact factor: 53.440

7.  Semi-quantitative fluorescent PCR analysis identifies PRKAA1 on chromosome 5 as a potential candidate cancer gene of cervical cancer.

Authors:  Fung Yu Huang; Pui Man Chiu; Kar Fai Tam; Yvonne K Y Kwok; Elizabeth T Lau; Mary H Y Tang; Tong Yow Ng; Vincent W S Liu; Annie N Y Cheung; Hextan Y S Ngan
Journal:  Gynecol Oncol       Date:  2006-04-03       Impact factor: 5.482

8.  Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1.

Authors:  Isaam Ben Sahra; Claire Regazzetti; Guillaume Robert; Kathiane Laurent; Yannick Le Marchand-Brustel; Patrick Auberger; Jean-François Tanti; Sophie Giorgetti-Peraldi; Frédéric Bost
Journal:  Cancer Res       Date:  2011-05-03       Impact factor: 12.701

9.  Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply.

Authors:  Andrew Y Choo; Sang Gyun Kim; Matthew G Vander Heiden; Sarah J Mahoney; Hieu Vu; Sang-Oh Yoon; Lewis C Cantley; John Blenis
Journal:  Mol Cell       Date:  2010-05-28       Impact factor: 17.970

Review 10.  NUAK2: an emerging acral melanoma oncogene.

Authors:  Takeshi Namiki; Sergio G Coelho; Vincent J Hearing
Journal:  Oncotarget       Date:  2011-09
View more
  130 in total

1.  Role of Runx2 in IGF-1Rβ/Akt- and AMPK/Erk-dependent growth, survival and sensitivity towards metformin in breast cancer bone metastasis.

Authors:  M Tandon; Z Chen; A H Othman; J Pratap
Journal:  Oncogene       Date:  2016-01-25       Impact factor: 9.867

2.  When Anti-Aging Studies Meet Cancer Chemoprevention: Can Anti-Aging Agent Kill Two Birds with One Blow?

Authors:  Noriko N Yokoyama; Andria Denmon; Edward M Uchio; Mark Jordan; Dan Mercola; Xiaolin Zi
Journal:  Curr Pharmacol Rep       Date:  2015-04-14

3.  Effect of Sishen Pill on Memory T Cells From Experimental Colitis Induced by Dextran Sulfate Sodium.

Authors:  Wei Ge; Hai-Yan Wang; Hai-Mei Zhao; Xue-Ke Liu; You-Bao Zhong; Jian Long; Zheng-Yun Zuo; Duan-Yong Liu
Journal:  Front Pharmacol       Date:  2020-07-02       Impact factor: 5.810

4.  Myristoylation confers noncanonical AMPK functions in autophagy selectivity and mitochondrial surveillance.

Authors:  Jiyong Liang; Zhi-Xiang Xu; Zhiyong Ding; Yiling Lu; Qinghua Yu; Kaitlin D Werle; Ge Zhou; Yun-Yong Park; Guang Peng; Michael J Gambello; Gordon B Mills
Journal:  Nat Commun       Date:  2015-08-14       Impact factor: 14.919

5.  AMPK Activation by Metformin Promotes Survival of Dormant ER+ Breast Cancer Cells.

Authors:  Riley A Hampsch; Jason D Wells; Nicole A Traphagen; Charlotte F McCleery; Jennifer L Fields; Kevin Shee; Lloye M Dillon; Darcy B Pooler; Lionel D Lewis; Eugene Demidenko; Yina H Huang; Jonathan D Marotti; Abigail E Goen; William B Kinlaw; Todd W Miller
Journal:  Clin Cancer Res       Date:  2020-04-22       Impact factor: 12.531

6.  Akt activation by Ca2+/calmodulin-dependent protein kinase kinase 2 (CaMKK2) in ovarian cancer cells.

Authors:  Angela M Gocher; Gissou Azabdaftari; Lindsey M Euscher; Shuhang Dai; Loukia G Karacosta; Thomas F Franke; Arthur M Edelman
Journal:  J Biol Chem       Date:  2017-06-20       Impact factor: 5.157

7.  A new duet in cancer biology: AMPK the typical and UBE2O the atypical.

Authors:  Isabelle K Vila; Su Jung Song; Min Sup Song
Journal:  Mol Cell Oncol       Date:  2017-03-17

8.  AMPKα2 Regulates Bladder Cancer Growth through SKP2-Mediated Degradation of p27.

Authors:  Stavros Kopsiaftis; Katie L Sullivan; Isha Garg; John A Taylor; Kevin P Claffey
Journal:  Mol Cancer Res       Date:  2016-09-16       Impact factor: 5.852

Review 9.  Dysregulated glycolysis as an oncogenic event.

Authors:  Takumi Mikawa; Matilde E LLeonart; Akifumi Takaori-Kondo; Nobuya Inagaki; Masayuki Yokode; Hiroshi Kondoh
Journal:  Cell Mol Life Sci       Date:  2015-01-22       Impact factor: 9.261

10.  Adenosine enhances cisplatin sensitivity in human ovarian cancer cells.

Authors:  Parichat Sureechatchaiyan; Alexandra Hamacher; Nicole Brockmann; Bjoern Stork; Matthias U Kassack
Journal:  Purinergic Signal       Date:  2018-08-04       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.